Yahong Pharmaceuticals: APL-1401 Phase Ib clinical trial receives positive preliminary results.

date
03/08/2025
Yahong Pharmaceutical announced that the phase Ib clinical trial of APL-1401, developed by the company for the treatment of moderate to severe active ulcerative colitis, has achieved positive preliminary results. APL-1401 is a potent and selective dopamine -hydroxylase inhibitor that blocks dopamine synthesis by inhibiting DBH, the only enzyme responsible for the conversion of dopamine to norepinephrine. This results in an increase in dopamine and a decrease in norepinephrine, restoring intestinal immune homeostasis. Currently, there is no cure for ulcerative colitis, and the development of APL-1401 is expected to provide new treatment options for UC patients.